EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer

The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (X...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2010-03, Vol.21 (3), p.535-539
Hauptverfasser:	Spindler, K.-L. G., Andersen, R.F., Jensen, L.H., Ploen, J., Jakobsen, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Capecitabine Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives DNA-Binding Proteins - genetics EGF61A>G Endonucleases - genetics Epidermal Growth Factor - genetics ERCC1 118 Feasibility Studies Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Gastroenterology. Liver. Pancreas. Abdomen gene polymorphisms Humans Male mCRC Medical sciences Middle Aged Neoplasm Staging Organoplatinum Compounds - administration & dosage Oxaliplatin Pharmacology. Drug treatments Polymorphism, Genetic - genetics Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Survival Rate Thymidylate Synthase - genetics Treatment Outcome Tumors XELOX
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!